Focus: Taiho Oncology is a 5,000+ employee oncology-focused biotech subsidiary headquartered in Princeton, NJ, specializing in small-molecule therapeutics for solid tumors and hematologic malignancies. The company operates as part of a larger parent organization with established commercial infrastructure and global reach.
Profile data last refreshed 2d ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Taiho Oncology to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Taiho Oncology
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Taiho Oncology's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Flagship asset representing 68% of company revenue; nucleoside analog addressing refractory solid tumors with 13+ year LOE runway.
Oral nucleoside metabolic inhibitor with 17+ year LOE protection; second-largest revenue contributor addressing hematologic malignancies.
Precision FGFR inhibitor addressing narrow but high-unmet-need indication; demonstrates pipeline-to-commercial capability on targeted therapies.
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo